NANJING KING-FRIEND BIOCHEMICAL PHARMACEUTICAL CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13.81 CNY | +2.60% |
|
-0.65% | -7.93% |
| May. 13 | NKFPharma's Unit Gets FDA's Nod to Market Eptifibatide Injection in US | MT |
| May. 01 | NKFPharma Gets Nod to Register New Cancer Treatment | MT |
Evolution of the average Target Price on Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd.
Price target over the last 5 years
History of analyst recommendation changes
92466df52c40e758d059aa349569560.PpO_4yiXhylsCJSmQ-lo81SMwRkaFf9Y8JbjZw4C9NI.WMX7gmegtEslcuPCO59du2XoiU9xLK91m8WoF31hgJtr5Nm8QPPTWF5f2Q~433c140547b07ecef1ddddb6b1e98433
Analysts' Consensus
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
13.81
CNY
Average target price
15.82
CNY
Spread / Average Target
+14.52%
High Price Target
16
CNY
Spread / Highest target
+15.86%
Low Price Target
15.63
CNY
Spread / Lowest Target
+13.18%
Consensus detail
Consensus revision (last 18 months)
Trading Rating
Investor Rating
ESG Refinitiv
D
EPS Revisions
Annual profits - Rate of surprise
- Stock Market
- Equities
- 603707 Stock
- Consensus Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd.
